ACRS
Price
$3.26
Change
+$0.24 (+7.95%)
Updated
Dec 17, 04:59 PM (EDT)
64 days until earnings call
DXCM
Price
$77.84
Change
+$1.43 (+1.87%)
Updated
Dec 17, 04:59 PM (EDT)
50 days until earnings call
Ad is loading...

ACRS vs DXCM

Header iconACRS vs DXCM Comparison
Open Charts ACRS vs DXCMBanner chart's image
Aclaris Therapeutics
Price$3.26
Change+$0.24 (+7.95%)
Volume$39.77K
CapitalizationN/A
DexCom
Price$77.84
Change+$1.43 (+1.87%)
Volume$18.05K
CapitalizationN/A
ACRS vs DXCM Comparison Chart
Loading...
ACRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DXCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACRS vs. DXCM commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRS is a Hold and DXCM is a Hold.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (ACRS: $3.26 vs. DXCM: $77.80)
Brand notoriety: ACRS and DXCM are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ACRS: 47% vs. DXCM: 87%
Market capitalization -- ACRS: $87.95M vs. DXCM: $53.47B
ACRS [@Medical Specialties] is valued at $87.95M. DXCM’s [@Medical Specialties] market capitalization is $53.47B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACRS’s FA Score shows that 0 FA rating(s) are green whileDXCM’s FA Score has 1 green FA rating(s).

  • ACRS’s FA Score: 0 green, 5 red.
  • DXCM’s FA Score: 1 green, 4 red.
According to our system of comparison, ACRS is a better buy in the long-term than DXCM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACRS’s TA Score shows that 4 TA indicator(s) are bullish while DXCM’s TA Score has 3 bullish TA indicator(s).

  • ACRS’s TA Score: 4 bullish, 4 bearish.
  • DXCM’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ACRS is a better buy in the short-term than DXCM.

Price Growth

ACRS (@Medical Specialties) experienced а -10.19% price change this week, while DXCM (@Medical Specialties) price change was -0.78% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.60%. For the same industry, the average monthly price growth was +3.56%, and the average quarterly price growth was +2.24%.

Reported Earning Dates

ACRS is expected to report earnings on Feb 20, 2025.

DXCM is expected to report earnings on Feb 06, 2025.

Industries' Descriptions

@Medical Specialties (-2.60% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DXCM($53.5B) has a higher market cap than ACRS($87.9M). ACRS YTD gains are higher at: 210.476 vs. DXCM (-37.304). DXCM has higher annual earnings (EBITDA): 917M vs. ACRS (-115.45M). DXCM has more cash in the bank: 2.72B vs. ACRS (119M). ACRS has less debt than DXCM: ACRS (426K) vs DXCM (2.59B). DXCM has higher revenues than ACRS: DXCM (3.62B) vs ACRS (31.2M).
ACRSDXCMACRS / DXCM
Capitalization87.9M53.5B0%
EBITDA-115.45M917M-13%
Gain YTD210.476-37.304-564%
P/E RatioN/A106.11-
Revenue31.2M3.62B1%
Total Cash119M2.72B4%
Total Debt426K2.59B0%
FUNDAMENTALS RATINGS
ACRS vs DXCM: Fundamental Ratings
ACRS
DXCM
OUTLOOK RATING
1..100
9018
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
77
Overvalued
PROFIT vs RISK RATING
1..100
9174
SMR RATING
1..100
9529
PRICE GROWTH RATING
1..100
3462
P/E GROWTH RATING
1..100
10094
SEASONALITY SCORE
1..100
2n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACRS's Valuation (36) in the Pharmaceuticals Other industry is somewhat better than the same rating for DXCM (77) in the Medical Specialties industry. This means that ACRS’s stock grew somewhat faster than DXCM’s over the last 12 months.

DXCM's Profit vs Risk Rating (74) in the Medical Specialties industry is in the same range as ACRS (91) in the Pharmaceuticals Other industry. This means that DXCM’s stock grew similarly to ACRS’s over the last 12 months.

DXCM's SMR Rating (29) in the Medical Specialties industry is significantly better than the same rating for ACRS (95) in the Pharmaceuticals Other industry. This means that DXCM’s stock grew significantly faster than ACRS’s over the last 12 months.

ACRS's Price Growth Rating (34) in the Pharmaceuticals Other industry is in the same range as DXCM (62) in the Medical Specialties industry. This means that ACRS’s stock grew similarly to DXCM’s over the last 12 months.

DXCM's P/E Growth Rating (94) in the Medical Specialties industry is in the same range as ACRS (100) in the Pharmaceuticals Other industry. This means that DXCM’s stock grew similarly to ACRS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACRSDXCM
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
70%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
66%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 13 days ago
83%
Bullish Trend 9 days ago
74%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Ad is loading...
ACRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DXCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LQDA11.310.28
+2.54%
Liquidia Corp
BARK2.190.03
+1.39%
BARK
STE209.51-1.52
-0.72%
STERIS plc
ZGN8.67-0.20
-2.25%
Ermenegildo Zegna NV
GRFX0.19N/A
-2.38%
Graphex Group Limited

ACRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACRS has been loosely correlated with PLLWF. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRS jumps, then PLLWF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACRS
1D Price
Change %
ACRS100%
+7.95%
PLLWF - ACRS
64%
Loosely correlated
N/A
MYNZ - ACRS
40%
Loosely correlated
-6.62%
UFPT - ACRS
39%
Loosely correlated
+2.60%
ANIK - ACRS
34%
Loosely correlated
-1.89%
DXCM - ACRS
33%
Loosely correlated
+1.82%
More

DXCM and

Correlation & Price change

A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with CERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then CERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DXCM
1D Price
Change %
DXCM100%
+1.82%
CERS - DXCM
42%
Loosely correlated
-6.11%
IRMD - DXCM
34%
Loosely correlated
-0.34%
AORT - DXCM
33%
Loosely correlated
-0.21%
ACRS - DXCM
33%
Loosely correlated
+7.95%
COO - DXCM
32%
Poorly correlated
+0.54%
More